Tanimoto Sarina, Chief Medical Officer at an undisclosed company, has demonstrated a clear selling bias in her recent insider transactions, exclusively divesting shares of SPRY (Spruce Biosciences) across 23 filings since February 2024. Her sales have totaled approximately $3.46 million, with no recorded purchases during this period. The transactions reveal a pattern of concentrated disposals, particularly in late February and March 2024, when she executed multiple sales totaling over $1.3 million within weeks. Notably, her largest single-day disposals occurred on March 15 ($442,996 and $441,488) and August 20, 2025 ($530,625), suggesting strategic timing around specific price levels or corporate events.
The sales volume fluctuated significantly, ranging from small dispositions under $10,000 to six-figure transactions. For instance, on February 28, 2024, she sold shares worth $219,225, $442,210, and $229,625 in separate filings, while other dates saw minor sales below $10,000. The absence of any acquisition activity—coupled with the consistency of disposals—indicates a sustained reduction in her SPRY holdings. While the filings do not specify whether these sales were pre-planned (such as 10b5-1 transactions), the data reflects a deliberate and ongoing liquidation of her position in the biopharmaceutical company.
AI-assisted summary